Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of fremanezumab for migraine prevention in children and adolescents
NL-OMON60536Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fremanezumab in migraine and chronic migraine, sponsored by Teva Pharmaceutical Industries Ltd. Started Oct 2020; status: completed.
02
Drugs
fremanezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on NL-OMON60536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60536.